4.8 Article

PKCα phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity

期刊

ONCOGENE
卷 32, 期 8, 页码 1010-1017

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2012.124

关键词

RhoGDI2; phosphorylation; GTPase; PKC alpha

资金

  1. National Institutes of Health [CA143971]
  2. Paul Mellon Urologic Cancer Institute (Charlottesville, VA)

向作者/读者索取更多资源

Rho family GTPases control a diverse range of cellular processes, and their deregulation has been implicated in human cancer. Guanine nucleotide dissociation inhibitors (GDIs) bind and sequester GTPases in the cytosol, restricting their actions. RhoGDI2 is a member of the GDI family that acts as a metastasis suppressor in a variety of cancer types; however, very little is known about the regulation of this protein. Here, we present a mechanism for inactivation of RhoGDI2 via protein kinase C (PKC) phosphorylation of Ser31 in a region that contacts GTPases. In cells, RhoGDI2 becomes rapidly phosphorylated at Ser31 in response to phorbol 12-myristate 13-acetate stimulation. Based on the effects of pharmacological inhibitors and knockdown by siRNA, we determine that conventional type PKC alpha is responsible for this phosphorylation. Phospho-mimetic S31E-RhoGDI2 exhibits reduced binding to Rac1 relative to wild type, with a concomitant failure to reduce levels of activated endogenous Rac1 or remove Rac1 from membranes. These results reveal a mechanism of downregulation of RhoGDI2 activity through PKC-mediated phosphorylation of Ser31. We hypothesize that this mechanism may serve to neutralize RhoGDI2 function in tumors that express RhoGDI2 and active PKCa. Oncogene (2013) 32, 1010-1017; doi:10.1038/onc.2012.124; published online 2 April 2012

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

The origin of bladder cancer from mucosal field effects

Jolanta Bondaruk, Roman Jaksik, Ziqiao Wang, David Cogdell, Sangkyou Lee, Yujie Chen, Khanh Ngoc Dinh, Tadeusz Majewski, Li Zhang, Shaolong Cao, Feng Tian, Hui Yao, Pawek Kus, Huiqin Chen, John N. Weinstein, Neema Navai, Colin Dinney, Jianjun Gao, Dan Theodorescu, Christopher Logothetis, Charles C. Guo, Wenyi Wang, David McConkey, Peng Wei, Marek Kimmel, Bogdan Czerniak

Summary: Whole-organ mapping identified dysregulated pathways and immune response involvement in bladder cancer development. Aberrant methylation/expression of genes and different types of mutations were found to be associated with disease progression. The carcinogenesis process can be divided into dormant and progressive phases.

ISCIENCE (2022)

Review Oncology

Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors

Christa M. Lam, Zihai Li, Dan Theodorescu, Xue Li

Summary: The incidence of bladder cancer is higher in males than females, regardless of geographical, racial, or socioeconomic factors. Despite potential differences in tumor biology, male and female bladder cancer patients are managed similarly. Advances in genomic technology have shed light on complex sex-biasing factors such as epigenetics, single nucleotide polymorphism, metabolism, and immunity. Understanding sex-biasing effects can inform precision medicine efforts based on a patient's biological sex.

BLADDER CANCER (2022)

Review Urology & Nephrology

Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guerin Failure

Michael Nazmifar, Cheyenne Williams, Aurash Naser-Tavakolian, John Heard, Charles Rosser, Dan Theodorescu, Michael Ahdoot

Summary: The purpose of this study is to evaluate the efficacy of various therapeutic agents for high-grade nonmuscle-invasive bladder cancer following failed bacillus Calmette-Guerin treatment. A systematic review of available clinical trials was conducted, and a total of 70 studies evaluating 27 treatment options were analyzed. Intravesical chemotherapy and hyperthermia paired with chemotherapy demonstrated high complete response rates, while immunotherapy and novel agents also showed promising results. The treatments had low toxicity profiles and complication rates.

JOURNAL OF UROLOGY (2023)

Article Biochemistry & Molecular Biology

CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners

Christian Soehngen, David J. Thomas, Margaretha A. Skowron, Felix Bremmer, Markus Eckstein, Anja Stefanski, Marc D. Driessen, Gamal A. Wakileh, Kai Stuehler, Peter Altevogt, Dan Theodorescu, Ruediger Klapdor, Axel Schambach, Daniel Nettersheim

Summary: This study aimed to understand the molecular function of CD24 in vitro and evaluate the cytotoxic capacity of NK cell CAR against CD24 in urological tumor cells. The results showed that CD24 interacts with proteins involved in cell adhesion, ATP binding, phosphoprotein binding, and post-translational modifications. Treatment with NK-CD24-CAR cells significantly decreased cell viability and induced apoptosis specifically in CD24(+) tumor cells. This study provides a promising novel target for immune therapeutic approaches against urological malignancies.

FEBS JOURNAL (2023)

Article Multidisciplinary Sciences

Y chromosome loss in cancer drives growth by evasion of adaptive immunity

Hany A. Abdel-Hafiz, Johanna M. Schafer, Xingyu Chen, Tong Xiao, Timothy D. Gauntner, Zihai Li, Dan Theodorescu

Summary: Loss of the Y chromosome (LOY) correlates with poor prognoses in bladder cancer patients. LOY mutations alter T cell function, promoting T cell exhaustion and sensitizing them to PD-1-targeted immunotherapy.

NATURE (2023)

Article Cell Biology

Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin

Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C. J. van der Made, Egbert R. Boeve, Deric K. E. van der Schoot, Bart Nieuwkamer, Emiel A. M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C. M. Zuiverloon

Summary: The recommended treatment for high-risk non-muscle-invasive bladder cancer patients is tumor resection followed by adjuvant Bacillus Calmette-Guerin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. Identifying tumors unlikely to respond to BCG can lead to alternative treatments for these patients.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Review Oncology

Identifying novel biomarkers associated with bladder cancer treatment outcomes

Peris R. Castaneda, Dan Theodorescu, Charles J. Rosser, Michael Ahdoot

Summary: Bladder cancer is a complex disease with variable prognosis, and recent studies have identified frequent genetic alterations and molecular subtypes. Personalized treatment strategies and the development of biomarkers to predict response and guide therapy in bladder cancer have become a focus of research. In this review, we summarize the latest studies on novel biomarkers in bladder cancer, specifically those intended to improve risk stratification and treatment selection, based on a search of recently published PubMed articles using relevant keywords.

FRONTIERS IN ONCOLOGY (2023)

Article Urology & Nephrology

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314 NCT02177695) ;

Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Shivaram Alva, M. Scott Lucia, David James McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson Jr, Seth P. Lerner

Summary: This article mainly evaluated the predictive role of the COXEN gene expression model in neoadjuvant chemotherapy for bladder cancer, and conducted a secondary analysis of the association between COXEN scores and event-free survival and overall survival.

EUROPEAN UROLOGY (2023)

Article Biology

A novel single alpha-helix DNA-binding domain in CAF-1 promotes gene silencing and DNA damage survival through tetrasome-length DNA selectivity and spacer function

Ruben Rosas, Rhiannon R. Aguilar, Nina Arslanovic, Anna Seck, Duncan J. Smith, Jessica K. Tyler, Mair E. A. Churchill

Summary: The histone chaperone CAF-1 deposits histone H3/H4 dimers onto newly replicated DNA to form the central core of the nucleosome tetrasome. The KER SAH region of CAF-1 plays a crucial role in ensuring the assembly of tetrasomes by linking functional domains within CAF-1 with structural precision.
Review Medicine, General & Internal

Bladder cancer

Lars Dyrskjot, Donna E. Hansel, Jason A. Efstathiou, Margaret A. Knowles, Matthew D. Galsky, Jeremy Teoh, Dan Theodorescu

Summary: Bladder cancer is a global health issue with distinct molecular subtypes and pathogenic pathways. Early detection and diagnosis are crucial for improving patient outcomes. Treatment options vary depending on the invasion level and include surgery and immunotherapy. Effective management requires a multidisciplinary approach that considers patient characteristics and molecular disease characteristics.

NATURE REVIEWS DISEASE PRIMERS (2023)

Article Multidisciplinary Sciences

Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional with relevance

Hany A. Abdel-Hafiz, Saravana Kumar Kailasam Mani, Wesley Huang, I. I. I. Kenneth H. Gouin, Yuzhou Chang, Tong Xiao, Qin Ma, Zihai Li, Simon R. V. Knott, Dan Theodorescu

Summary: In this study, single-cell RNA sequencing was used to characterize cell-type specific transcriptional differences between male and female BBN-induced tumors. Proportional and gene expression differences were found in epithelial and non-epithelial subpopulations between male and female tumors. Several genes were found to predict sex-specific survival in human BLCA datasets. Novel and clinically relevant sex-specific transcriptional signatures were identified, including immune cells in the tumor microenvironment. It validated the relevance of the BBN model for studying sex differences in human BLCA.

ISCIENCE (2023)

Review Urology & Nephrology

Genetic and biological drivers of prostate cancer disparities in Black men

Jun Gong, Daniel M. Kim, Michael R. Freeman, Hyung Kim, Leigh Ellis, Bethany Smith, Dan Theodorescu, Edwin Posadas, Robert Figlin, Neil Bhowmick, Stephen J. Freedland

Summary: Black men with prostate cancer have biologically distinct cancers compared to white men, including genetic alterations, protein differences, and tumor microenvironment. Socioeconomic status partially explains the disparities, but not completely. Further research on these biological differences can guide efforts to improve treatment outcomes for Black men.

NATURE REVIEWS UROLOGY (2023)

Meeting Abstract Oncology

Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers

Matthew Mackay, Nicholas Mitsiades, Young Kwang Chae, Andrew A. Davis, Philip Edward Lammers, James F. Maher, Dan Theodorescu, Peter Rubin, Timothy J. Pluard, Lee Langer, Kabir Manghnani, Rotem Ben-Shachar, Kimberly L. Blackwell, James Lin Chen, Joel Dudley, Justin Guinney, Wade Thomas Iams

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Biochemistry & Molecular Biology

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes

Sebastien Rinaldetti, Qiong Zhou, Joshua M. Abbott, Florus C. de Jong, Hector Esquer, James C. Costello, Dan Theodorescu, Daniel LaBarbera

Summary: This study discovered novel subtype-stratified therapy approaches for bladder cancer based on high-content screening, and correlated drug sensitivity with functional genomics to validate and understand the underlying mechanisms.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Meeting Abstract Urology & Nephrology

Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

Jong F. C. De, T. D. Laajala, R. F. Hoedemaeker, S. Rinaldetti, K. Jordan, A. C. J. Van der Made, B. Nieuwkamer, E. R. Boeve, E. A. M. Janssen, T. Mahmoudi, J. L. Boormans, D. Theodorescu, J. C. Costello, T. C. M. Zuiverloon

EUROPEAN UROLOGY (2022)

暂无数据